Login to Your Account



Tysabri's Phase III Positive; Details Back Top-Line Data

By Randall Osborne


Thursday, April 14, 2005
Further bolstering the companies' hopes that the withdrawn multiple sclerosis drug Tysabri might one day become available again, Biogen Idec Inc. and Elan Corp. plc disclosed full two-year data from their Phase III monotherapy trial with the compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription